According to a report “Biologics Market Analysis By Source (Microbial, Mammalian), By Products (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi), By Disease Category, By Manufacturing, & Segment Forecasts, 2018 – 2025”, published by Grand View Research, Inc. The global biologics market is anticipated to reach USD 399.5 billion by 2025, according to a new report by Grand View Research, Inc. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine anticipated to fuel demand. Ever-increasing understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression have empowered the use of different living factories.
Key Takeaways from the report:
U.S. Biologics market share, by disease category, 2014 – 2025 (USD Billion)
Browse More Reports in Medical Devices Industry:
Protein Expression Market – Growing demand for novel biologic product for the treatment of severe chronic diseases such as cancer, anemia, and multiple sclerosis is a major factor contributing toward the growth of the protein expression market.
Aptamers Market – The aptamers market is expected to grow due to advancements in technologies, i.e., Systemic Evolution of Ligands by Exponential Enrichment (SELEX) process.
Biologics market, by region, 2015 (USD Billion)
These living factories are the prokaryotic and eukaryotic cells. Enhancement of drug functionality through achieving successful protein folding and post-translational modifications is supportive for projected progress rate.
Moreover, rising adoption of biopharmaceuticals over chemically synthesized molecules is expected to propel revenue generation significantly. In addition to this, presence of several metabolic disorders that can be treated through the use of biologics is attributive to influence demand.
Combination of advanced bioengineering technologies for biopharmaceutical production is expected to boost progress in pharmaceutical industry. With recent advances in automation, the selection process can be done through high throughput screening (HTS) system for selection of viable clones.
Aforementioned method enables robust production of biopharmaceutical products by obtaining high-producing cell line. Advances with respect to upstream and downstream processing would directly translate into the growth in revenue for this market at a larger level.
However, development of biosimilars is expected to restrain the biologics year on year growth to certain extent. Although, the regulatory approval pathway for these products is not framed yet some drug manufacturers are opting to invest in the development of biobetters.
Grand View Research has segmented the biologics market on the basis of source, product, manufacturing, disease category, and region:
Biologics Source Outlook (Revenue, USD Billion, 2014 – 2025)
Biologics Product Outlook (Revenue, USD Billion, 2014 – 2025)
Biologics Manufacturing Outlook (Revenue, USD Billion, 2014 – 2025)
Biologics Disease Category Outlook (Revenue, USD Billion, 2014 – 2025)
Biologics Regional Outlook (Revenue, USD Billion, 2014 – 2025)
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com
Media ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.Email: Send EmailPhone: 1-415-349-0058, Toll Free: 1-888-202-9519Address:201, Spear Street, 1100 City: San FranciscoState: CaliforniaCountry: United StatesWebsite: www.grandviewresearch.com/industry-analysis/biologics-market